Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine, Inc. (Nasdaq: EDIT) will host a conference call on May 8, 2024, to discuss first quarter 2024 results and provide a corporate update. The company will also participate in several upcoming investor events, including the Bank of America Health Care Conference and RBC Capital Markets Global Healthcare Conference.
Editas Medicine, Inc. (Nasdaq: EDIT) has extended its collaboration with Bristol Myers Squibb (NYSE: BMY) for two more years to research, develop, and commercialize alpha-beta T cell medicines for cancer and autoimmune diseases. Bristol Myers Squibb has opted into 13 programs across 11 gene targets, with potential milestone payments and royalties for Editas Medicine. The collaboration aims to create the next generation of allogeneic medicines to combat various cancers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.